In summary, we firstly demonstrates that miR-3646 contributes to drug resistance of breast cancer cells to Doc at least in part through activation of GSK-3β/β-catenin pathway by suppressing expression of GSK-3β. The gene discussed is GSK3B; the disease is breast carcinoma.